gdc
FDA Approvals, News & UpdatesMultiple Myeloma

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
April 2021 Vol 7 No 2

In February 2021, the FDA approved Pepaxto (melphalan flufenamide; from Oncopeptides AB), for the treatment (in combination with dexamethasone) of adults with relapsed or refractory multiple myeloma who had received 4 or more lines of therapy and whose disease has not responded to 3 types of drugs, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Pepaxto is the first peptide–drug conjugate approved for multiple myeloma.

“Research has shown melphalan flufenamide to be a novel and innovative therapeutic option, which is active in refractory disease and has manageable toxicity, with the convenience of being administered by infusion once a month,” said Paul G. Richardson, MD, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. “Based on our findings, melphalan flufenamide is an important addition to the treatment armamentarium, with the potential to meaningfully improve outcomes in an area of important unmet medical need.”

This approval was based on results for 97 patients with relapsed or refractory multiple myeloma who previously received 4 or more therapies. The patients received intravenous Pepaxto on day 1 and oral dexamethasone on days 1, 8, 15, and 22 of every 28-day cycle, until disease progression or until unacceptable side effects.

The overall response rate was 23.7% and the average duration of response was 4.2 months.

The most common side effects with melphalan flufenamide were fatigue, nausea, diarrhea, fever, and respiratory tract infection.

Share this:

Recommended For You
Breast CancerFDA Approvals, News & Updates
Drug Watch: Recently FDA-Approved Breast Cancer Treatments
There are more treatment options available for breast cancer than ever before – and more are coming. Here’s an overview of the most recently approved medicines.
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
“Today’s approval represents another milestone in the rapidly progressing field of gene therapy,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma.
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta First Gene Therapy Approved for Follicular Lymphoma
Yescarta is the first CAR T-cell therapy approved by the FDA for patients with follicular lymphoma. It uses the patient’s own genetically modified T-cells to fight the cancer.
Last modified: April 28, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country